Chemomab Therapeutics (CMMB)

• Market cap: $9.6M
• 1 day: 10.08%
• 5 days: -40.45%
• 1 month: -52.01%
• 3 months: -22.94%
• 6 months: -17.61%
• Year to date: -26.82%
• 1 year: -50.38%
• 5 years: -96.97%
• 10 years: -99.81%
• Sector: Healthcare
• Industry: Biotechnology

About: Chemomab Therapeutics Ltd is a clinical-stage biotechnology company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin, and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life-threatening fibrotic and inflammatory diseases.

Employees: 12